ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
iSpecimen Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.91−0.01 (-0.75%)
Close on Oct 19, 2026
- Market cap
- $1.27M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$28.7219 (−96.93%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
iSpecimen Inc. saw revenue fall 92.1% to $466.30K over the twelve months to Jun 30, 2026. Free cash flow was -$4.24M.
Revenue
$466.30K
-92.1% vs. a year earlier
Operating income
-$9.42M
TTM Q2 2026
Free cash flow
-$4.24M
FY2025
EPS, diluted
-$52.78
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.27M
- P/E ratio
- –
- Price to sales
- 2.72
- Price to book
- 0.73
- Dividend yield
- –
- Free cash flow yield
- -334.17%
Fundamentals
- Revenue
- $466.30K
- Net income
- -$11.42M
- EPS, diluted
- -$52.78
- Free cash flow
- -$4.24M
- Book value per share
- $1.25
- Diluted shares
- 1M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$466.30K-92.1% YoY
Gross profit
-$456.94K-123.1% YoY
Operating income
-$9.42M
Net income
-$11.42M
EPS, diluted
-$52.78
Free cash flow
–
Reported periodTrailing twelve months